Literatur zu

**Der Gerinnungsfaktor XIII**
Pathophysiologie, Klinik und Therapie von Mangelzuständen

Christian Friedrich Weber* • Elisabeth Hannah Adam* • Andreas Pape • Marina Jöst Patrick Meybohm • Katja Schmitz • Kai Zacharowski • Martin Hermann • Dietmar Fries


7 Mary A, Achyuthan KE, Greenberg CS. b-chains prevent the proteolytic inactivation of the a-chains of plasma factor XIII. BiochimBiophysActa 1988; 966: 328–335


16 Schroeder V, Vuissoz JM, Caflisch A, Kohler HP. Factor XIII activation peptide is released into plasma upon cleavage by thrombin and shows a different structure compared to its bound form. ThrombHaemost 2007; 97: 890–898


21 Fraser SR, Booth NA, Mutch NJ. The antifibrinolytic function of factor XIII is exclusively expressed through alpha(2)-antiplasmin cross-linking. Blood 2011; 117: 6371–6374


45 Trumbo TA, Maurer MC. Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor XIII V34L mutation. J Biol Chem 2000; 275: 20627–20631


53 Weber CF, Sanders JO, Friedrich K et al. Role of thrombelastometry for the monitoring of factor XIII. A prospective observational study in neurosurgical patients. Hamostaseologie 2011; 31: 111–117


58 Anwar R, Gallivan L, Edmonds SD, Markham AF. Genotype/phenotype correlations for coagulation factor XIII: specific normal polymorphisms are associated with high or low factor XIII specific activity. Blood 1999; 93: 897–905


62 Ichinose A. Physiopathology and regulation of factor XIII. ThrombHaemost 2001; 86: 57–65


75 Theusinger OM, Baulig W, Seifert B et al. Changes in coagulation in standard laboratory tests and ROTEM in trauma patients between on-scene and arrival in the emergency department. Anesth Analg 2015; 120: 627–635


